CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 ROR1 的抗体药物偶联物 zilovertamab vedotin 和 VLS-211 对 B 细胞急性淋巴细胞白血病患者来源异种移植模型的临床前评价

Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.

一种新型抗 GD2/ROR1 双特异性抗体的体外特性研究：在神经母细胞瘤中展现肿瘤细胞杀伤效力，在 ROR1 阳性三阴性乳腺癌中具有跨癌种活性

In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity i

G/R-001 BsAb 可同时结合 GD2 和 ROR1，并在体外显示出显著的抗肿瘤活性。这些结果为 G/R-001 作为新型抗肿瘤治疗药物的进一步开发提供了有力的实验证据。

双靶向 CD155 增强 ROR1-CAR-T 细胞在卵巢癌中的抗肿瘤疗效

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer.

CD155 成为 OC 中 CAR-T 疗法一个有前景的治疗靶点。

接头 CAR 共表达在淋巴瘤单一及双重抗原丢失后保留 CAR-T 细胞疗效

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

慢性淋巴细胞白血病中的 Richter 转化：当前治疗挑战与不断演变的疗法

Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.

血液系统恶性肿瘤中靶向 ROR1 的治疗进展

Therapeutic advances in the targeting of ROR1 in hematological cancers.

套细胞淋巴瘤的当前治疗

Current Treatments in Mantle Cell Lymphoma.

靶向 ROR1 的可开关 CAR-T 细胞用于肿瘤治疗

ROR1-targeting switchable CAR-T cells for cancer therapy.

2022 年套细胞淋巴瘤：分子发病机制、风险分层、临床策略及当前与新型治疗的综合更新

Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatment

2022 年套细胞淋巴瘤的新方向

New Directions for Mantle Cell Lymphoma in 2022.